- **Financial Strength**: $13.3M cash, $1M/month burn, no debt – 12+ months of runway.
- **FDA-Cleared Robot**: First U.S. surgeries Q3 2025, India trial starts Q2 2025.
- **Key Differentiator**: Autonomous cutting reduces surgeon fatigue, costs $1.2M less per case vs. Mako.
- **Growth Catalyst**: 70% of new surgeons trained on robots; Monogram targets 9% market share by 2031.
- **Next-Gen Hardware**: Upgraded system tested in Q1, FDA-cleared robots upgradable to new version.
- **Capital Plan**: Seeking funding to scale post-demonstration of clinical success.

**【CFO Financial Summary】**
- **Cash Position**: $13.3 million as of Q1 2025, with monthly cash burn reduced to $0.8 million (down from $1.1-$1.2 million in 2024).
- **Burn Rate**: Projected $1 million/month for 2025, providing over 12 months of runway.
- **Clinical Trial Spend**: $1.2 million expected over 6-9 months for India trial.
- **Balance Sheet**: No debt, minimal warrant obligations, strong financial flexibility.

**【CEO Business Update】**
- **FDA Clearance**: mBôs TKA system received 510(k) approval in March 2025, enabling U.S. pilot placements.
- **Clinical Milestones**: 
  - India trial to begin within 90 days (robot en route), targeting first surgeries Q2 2025.
  - U.S. pilot placement with 4 surgeons expected Q3 2025.
- **Competitive Differentiators**: 
  - Autonomous saw-based cutting vs. Stryker's Mako (manual blade changes, higher cost).
  - AI-driven landmark placement for accuracy vs. manual operator dependency.
  - Streamlined pre-op pipeline and faster bone cutting (competitive with manual surgery).
- **Market Opportunity**: 
  - 70% Mako market share among fellowship-trained surgeons, driven by early exposure.
  - 9% potential Stryker market share growth by 2031 due to retiring surgeons.
- **System Enhancements**: 
  - Upgraded end effector, blade, and software tested in Q1 2025.
  - FDA-cleared system upgradable to next-gen hardware.

**【Q&A Highlights】**
- **India Trial Timing**: First surgeries expected late Q2/Q3 2025.
- **U.S. Launch Strategy**: Slow rollout with high surgeon support to ensure >90% utilization.
- **Capital Needs**: Exploring additional funding to accelerate growth post-pilot data.
- **Competitor Comparison**: Monogram aims to match Mako's workflow while reducing surgeon fatigue and cost.

Monogram Technologies Inc. (MGRM) Q1 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

MGRM(Delisted)

MGRM fundamentals

You can ask Aime